Sign Up
Stories
Biotech Pioneer Adds Dr. Heah
Share
4D Molecular Therapeutics Raises $300 Mi...
4DMT Presents Positive Interim Data
Advancements in Cancer Treatment and Mar...
Biopharma Innovator GeNeuro Discloses Pr...
Biotech Collaboration for Industry Innov...
Biotech Collaboration for Innovative Sol...
Overview
API
Dr. Theresa Heah is nominated to Curative Biotechnology's Board of Directors, known for her experience in the biomedical industry. Curative Biotechnology specializes in rare disease therapies, notably developing a Metformin-based eye drop for Age-Related Macular Degeneration.
Ask a question
How might Dr. Heah's expertise influence Curative Biotechnology's research and development strategies?
In what ways does Dr. Heah's appointment reflect a broader trend in the biotechnology industry?
What potential impact could the Metformin-based eye drop have on the treatment landscape for Age-Related Macular Degeneration?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage